韩正调研国家医保局 再为抗癌药降价站台

2018-07-11 佚名 新华社

韩正在国家医疗保障局调研时强调,积极回应社会关切 更好保障病有所医,增强人民群众获得感幸福感安全感。

中共中央政治局常委、国务院副总理韩正10日下午在国家医疗保障局调研并主持召开座谈会。韩正重点了解抗癌药降价、医保支付方式改革、治理高值医用耗材过度使用等工作开展情况,调研医疗保障制度改革、医疗保障扶贫、医疗救助等工作,结合观看异地就医结算平台演示,了解异地就医直接结算工作有关情况,与干部职工进行深入交流。

韩正强调,组建国家医疗保障局,是以习近平同志为核心的党中央作出的重大决策部署,是深化党和国家机构改革的重要组成部分。要认真贯彻优化协同高效原则,把党中央确定的改革举措落到实处,不断提高医疗保障水平,更好保障病有所医,增强人民群众的获得感、幸福感、安全感。

韩正表示,要坚持以人民为中心的发展思想,完善统一的城乡居民基本医疗保险制度和大病保险制度,着力解决医疗保障领域发展不平衡不充分问题。要千方百计保基本,坚持尽力而为、量力而行,聚焦基本医疗需求,满足人民群众最迫切的愿望和要求。要始终做到可持续,健全医保筹资机制,强化医保基金监管,确保医保资金合理使用、安全可控。要发挥好医保的基础性、引导性作用,实行医疗、医保、医药“三医联动”,形成协同推进医改的良好格局。

韩正强调,要积极回应社会关切,加快推进抗癌药降价,减轻医药费用负担,给人民群众带来实实在在的好处。要完善国家异地就医结算系统,健全异地就医结算机制,做好异地就医直接结算工作。要转变政府职能、提高政府效能,加快推进“互联网+医保”,提升医保服务的品质和便利性。要坚持高标准、严要求,抓好党风廉政建设,打造忠诚干净担当的高素质干部队伍。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1751462, encodeId=1ae51e514624d, content=<a href='/topic/show?id=3ba692039f7' target=_blank style='color:#2F92EE;'>#调研#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92039, encryptionId=3ba692039f7, topicName=调研)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=958d36313994, createdName=天堂的云, createdTime=Fri Nov 16 23:43:00 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280405, encodeId=dcb3128040597, content=<a href='/topic/show?id=1bd3338451e' target=_blank style='color:#2F92EE;'>#医保局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33845, encryptionId=1bd3338451e, topicName=医保局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Fri Jul 13 08:43:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314776, encodeId=d5ee1314e76a8, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jul 13 08:43:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425029, encodeId=534e1425029b7, content=<a href='/topic/show?id=c1219810ebf' target=_blank style='color:#2F92EE;'>#降价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98107, encryptionId=c1219810ebf, topicName=降价)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6933946754, createdName=30397605, createdTime=Fri Jul 13 08:43:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497181, encodeId=2a65149e181a2, content=<a href='/topic/show?id=82b440848a4' target=_blank style='color:#2F92EE;'>#国家医保局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40848, encryptionId=82b440848a4, topicName=国家医保局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82569313637, createdName=雕雕, createdTime=Fri Jul 13 08:43:00 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1751462, encodeId=1ae51e514624d, content=<a href='/topic/show?id=3ba692039f7' target=_blank style='color:#2F92EE;'>#调研#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92039, encryptionId=3ba692039f7, topicName=调研)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=958d36313994, createdName=天堂的云, createdTime=Fri Nov 16 23:43:00 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280405, encodeId=dcb3128040597, content=<a href='/topic/show?id=1bd3338451e' target=_blank style='color:#2F92EE;'>#医保局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33845, encryptionId=1bd3338451e, topicName=医保局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Fri Jul 13 08:43:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314776, encodeId=d5ee1314e76a8, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jul 13 08:43:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425029, encodeId=534e1425029b7, content=<a href='/topic/show?id=c1219810ebf' target=_blank style='color:#2F92EE;'>#降价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98107, encryptionId=c1219810ebf, topicName=降价)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6933946754, createdName=30397605, createdTime=Fri Jul 13 08:43:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497181, encodeId=2a65149e181a2, content=<a href='/topic/show?id=82b440848a4' target=_blank style='color:#2F92EE;'>#国家医保局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40848, encryptionId=82b440848a4, topicName=国家医保局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82569313637, createdName=雕雕, createdTime=Fri Jul 13 08:43:00 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1751462, encodeId=1ae51e514624d, content=<a href='/topic/show?id=3ba692039f7' target=_blank style='color:#2F92EE;'>#调研#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92039, encryptionId=3ba692039f7, topicName=调研)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=958d36313994, createdName=天堂的云, createdTime=Fri Nov 16 23:43:00 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280405, encodeId=dcb3128040597, content=<a href='/topic/show?id=1bd3338451e' target=_blank style='color:#2F92EE;'>#医保局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33845, encryptionId=1bd3338451e, topicName=医保局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Fri Jul 13 08:43:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314776, encodeId=d5ee1314e76a8, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jul 13 08:43:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425029, encodeId=534e1425029b7, content=<a href='/topic/show?id=c1219810ebf' target=_blank style='color:#2F92EE;'>#降价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98107, encryptionId=c1219810ebf, topicName=降价)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6933946754, createdName=30397605, createdTime=Fri Jul 13 08:43:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497181, encodeId=2a65149e181a2, content=<a href='/topic/show?id=82b440848a4' target=_blank style='color:#2F92EE;'>#国家医保局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40848, encryptionId=82b440848a4, topicName=国家医保局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82569313637, createdName=雕雕, createdTime=Fri Jul 13 08:43:00 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
    2018-07-13 sunylz
  4. [GetPortalCommentsPageByObjectIdResponse(id=1751462, encodeId=1ae51e514624d, content=<a href='/topic/show?id=3ba692039f7' target=_blank style='color:#2F92EE;'>#调研#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92039, encryptionId=3ba692039f7, topicName=调研)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=958d36313994, createdName=天堂的云, createdTime=Fri Nov 16 23:43:00 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280405, encodeId=dcb3128040597, content=<a href='/topic/show?id=1bd3338451e' target=_blank style='color:#2F92EE;'>#医保局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33845, encryptionId=1bd3338451e, topicName=医保局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Fri Jul 13 08:43:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314776, encodeId=d5ee1314e76a8, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jul 13 08:43:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425029, encodeId=534e1425029b7, content=<a href='/topic/show?id=c1219810ebf' target=_blank style='color:#2F92EE;'>#降价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98107, encryptionId=c1219810ebf, topicName=降价)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6933946754, createdName=30397605, createdTime=Fri Jul 13 08:43:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497181, encodeId=2a65149e181a2, content=<a href='/topic/show?id=82b440848a4' target=_blank style='color:#2F92EE;'>#国家医保局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40848, encryptionId=82b440848a4, topicName=国家医保局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82569313637, createdName=雕雕, createdTime=Fri Jul 13 08:43:00 CST 2018, time=2018-07-13, status=1, ipAttribution=)]
    2018-07-13 30397605
  5. [GetPortalCommentsPageByObjectIdResponse(id=1751462, encodeId=1ae51e514624d, content=<a href='/topic/show?id=3ba692039f7' target=_blank style='color:#2F92EE;'>#调研#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92039, encryptionId=3ba692039f7, topicName=调研)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=958d36313994, createdName=天堂的云, createdTime=Fri Nov 16 23:43:00 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280405, encodeId=dcb3128040597, content=<a href='/topic/show?id=1bd3338451e' target=_blank style='color:#2F92EE;'>#医保局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33845, encryptionId=1bd3338451e, topicName=医保局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Fri Jul 13 08:43:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314776, encodeId=d5ee1314e76a8, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jul 13 08:43:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425029, encodeId=534e1425029b7, content=<a href='/topic/show?id=c1219810ebf' target=_blank style='color:#2F92EE;'>#降价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98107, encryptionId=c1219810ebf, topicName=降价)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6933946754, createdName=30397605, createdTime=Fri Jul 13 08:43:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497181, encodeId=2a65149e181a2, content=<a href='/topic/show?id=82b440848a4' target=_blank style='color:#2F92EE;'>#国家医保局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40848, encryptionId=82b440848a4, topicName=国家医保局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82569313637, createdName=雕雕, createdTime=Fri Jul 13 08:43:00 CST 2018, time=2018-07-13, status=1, ipAttribution=)]

相关资讯

医保局局长亲自调研、中央首肯 “医改先锋”三明为何独占C位?

6月15-16日,国家医保局局长胡静林一行赴福建省三明市,调研医疗保障和医药卫生体制改革相关工作。在经历了挂牌后小半个月的沉淀,胡静林上任的“第一把火”选择调研三明模式,看似意料之外,其实情理之中。作为医改先锋的三明,作为曾经差点被省厅窒息掉的三明,能否全国复制?掌门人胡静林又有着怎样的深思熟虑?为什么是三明?自新一轮医改启动以来,诸如“深圳模式”、“广东模式”等有幸受到国家“点赞”的医改模

与其谈论医保局领导去三明传递什么信号 不如看看这篇医生的控诉

医保改革难以一蹴而就,从一位领导首次视察地更是难以遽下结论。更应该引起关注的,是医保支付过程中的矛盾已经越来越频繁递延到医院和患者端,影响医生和患者获得感的事实。解决这些问题,需要大智慧,更需要顶层设计。

国家医保局:开展专项招标采购 让抗癌药价下降

国家医保局正督促推动抗癌药加快降价,让群众有更多获得感。

国家医保局长首访三明,传递怎样信息?

据有关媒体报道,6月15日至16日,国家医疗保障局局长胡静林一行赴福建省三明市,调研医疗保障和医药卫生体制改革相关工作。调研组一行先后深入沙县高桥镇卫生院、沙县高桥镇新桥村卫生所、三明市医管中心沙县管理部、三明市医疗保障管理中心、三明市第一医院等地,与各机构负责人及基层工作人员交流,详细了解三明医改以及医保基金统筹整合、经办管理、信息化建设等情况。

招采合一,明年全国推行!

昨日(6月30日),蒲公英第十届(三明)年会暨国际制药项目管理协会(IPPM)研讨会在福建省三明召开。

国家医保局开会了!传递重要信号

开会!先传达了国务院对药品集采的要求;另外,医保局改变当前的招标采购模式,准备个试点。